Jingwu Zang, M.D., Ph.D.
Senior Vice President, Head of R&D China, GlaxoSmithKline
Jingwu Zang received his medical degree in Shanghai JiaoTong University School of Medicine (formerly Shanghai Second Medical University) and went on to earn his PhD in Immunology in Belgium, where he started his illustrious pursuit of a cure for multiple sclerosis through basic and clinical research. He later received an advanced research fellowship award from US National Multiple Sclerosis Society and conducted his postdoctoral research on multiple sclerosis in Harvard Medical School.
Dr. Zang joined faculty of Neurology and Immunology at Baylor College of Medicine and obtained a US medical licensure through a clinical residency program there. Prior to his career in Shanghai, he had been Professor of Neurology and Immunology and Research Director of Multiple Sclerosis Center at Baylor College of Medicine in Texas. Dr. Zang has published more than 160 scientific articles in prestigious journals, chapters and books and received many international science awards. He is well known for his pioneering work in T cell vaccination as a treatment for multiple sclerosis, which led to landmark publications in Science. Dr. Zang was the scientific founder of Opexa Pharmaceuticals, a spin-off biotech company of Baylor College of Medicine.
In his recent career in China, Dr. Zang established the Institute of Health Sciences with Chinese Academy of Sciences as the founding director and the Institut Pasteur Shanghai (Chinese Academy of Sciences and Institut Pasteur Paris) as the Chinese founding director. Among other academic positions he held in China are Dean of School of Medical Sciences (Shanghai JiaoTong University) and Director of Shanghai Institute of Immunology. In June 2007, Dr. Zang joined GlaxoSmithKline as Senior Vice President to head GSK R&D Center in China.
Major research interests: Immune circuits (Th1, Th 17 and regulatory T cells) in autoimmune diseases.
